Harry L.A. Janssen

Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction.

FIB-4-based Referral Pathways Have Suboptimal Accuracy to Identify Increased Liver Stiffness and Incident Advanced Liver Disease

Management of immune-tolerant chronic hepatitis B.

A Comparison of the Predictive Value of 12 Body Composition Markers for Metabolic Dysfunction-Associated Steatotic Liver Disease, At-Risk Metabolic Dysfunction-Associated Steatohepatitis, and Increased Liver Stiffness in a General Population Setting.

Effectiveness and tolerability of bezafibrate in primary biliary cholangitis - a nationwide real-world study.

Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial.

A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection

A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection.

Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction.

Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.

Predictors of hepatic flares after nucleos(t)ide analogue cessation – Results of a global cohort study (RETRACT-B study)

Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials

PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.

HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy.

Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe.

Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis

Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis

Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection.

Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study).

Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study.

Intrahepatic plasma cells, but not atypical memory B cells, associate with clinical phases of chronic hepatitis B.

Liver-restricted Type I IFN Signature Precedes Liver Damage in Chronic Hepatitis B Patients Stopping Antiviral Therapy.

Incidence and prevalence of primary biliary cholangitis in the Netherlands - A nationwide cohort study.

Factors associated with knowledge and awareness of Hepatitis B in individuals of Chinese descent: Results from a mass point of care testing and outreach campaign in Toronto, Canada

Factors associated with knowledge and awareness of Hepatitis B in individuals of Chinese descent: Results from a mass point of care testing and outreach campaign in Toronto, Canada.

Reply: The exact predictive value of HBcrAg and HBV RNA in serological status and disease activity in CHB.

Increase in HDV replication during steroid therapy - potential implications for testing and treatment strategies.

Letter to the Editor: Benefits of stopping therapy in patients with cirrhotic hepatitis B, true effect or residual confounding?

Letter to the Editor: Provider preparedness for functional cure of chronic hepatitis B.

Real-world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada.